scholarly journals Self-Reporting Technologies for Supporting Epilepsy Treatment

Seizures ◽  
2018 ◽  
Author(s):  
Jonathan Bidwell ◽  
Eliana Kovich ◽  
Cam Escoffery ◽  
Cherise Frazier ◽  
Elizabeth D. Mynatt
Keyword(s):  
Epilepsy Treatment

scholarly journals Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances

2021 ◽  
Vol 18 (8) ◽  
pp. 3993
Author(s):  
Aaron M. Farrelly ◽  
Styliani Vlachou ◽  
Konstantinos Grintzalis
Keyword(s):  
Therapeutic Potential ◽  
Significant Proportion ◽  
Future Research ◽  
Specific Reference ◽  
Undesirable Side Effect ◽  
Treatment Resistant ◽  
Current Review ◽  
Epilepsy Treatment ◽  
Clinical Environments

Epilepsy is a neurological disorder mainly characterised by recurrent seizures that affect the entire population diagnosed with the condition. Currently, there is no cure for the disease and a significant proportion of patients have been deemed to have treatment-resistant epilepsy (TRE). A patient is deemed to have TRE if two or more antiepileptic drugs (AEDs) fail to bring about seizure remission. This inefficacy of traditional AEDs, coupled with their undesirable side effect profile, has led to researchers considering alternative forms of treatment. Phytocannabinoids have long served as therapeutics with delta-9-THC (Δ9-THC) receiving extensive focus to determine its therapeutic potential. This focus on Δ9-THC has been to the detriment of analysing the plethora of other phytocannabinoids found in the cannabis plant. The overall aim of this review is to explore other novel phytocannabinoids and their place in epilepsy treatment. The current review intends to achieve this aim via an exploration of the molecular targets underlying the anticonvulsant capabilities of cannabidiol (CBD), cannabidavarin (CBDV), delta-9-tetrahydrocannabivarin (Δ9-THCV) and cannabigerol (CBG). Further, this review will provide an exploration of current pre-clinical and clinical data as it relates to the aforementioned phytocannabinoids and the treatment of epilepsy symptoms. With specific reference to epilepsy in young adult and adolescent populations, the exploration of CBD, CBDV, Δ9-THCV and CBG in both preclinical and clinical environments can guide future research and aid in the further understanding of the role of phytocannabinoids in epilepsy treatment. Currently, much more research is warranted in this area to be conclusive.

Insights into the novel three ‘D's of epilepsy treatment: drugs, delivery systems and devices

2010 ◽  
Vol 15 (17-18) ◽  
pp. 717-732 ◽  
Author(s):  
Shadab A. Pathan ◽  
Gaurav K. Jain ◽  
Sohail Akhter ◽  
Divya Vohora ◽  
Farhan J. Ahmad ◽  
...  
Keyword(s):  
Delivery Systems ◽  
The Novel ◽  
Epilepsy Treatment

Epilepsy treatment in The Netherlands Comparison of matched groups of two medical centres

2009 ◽  
Vol 89 (6) ◽  
pp. 415-420 ◽  
Author(s):  
M. W. Lammers ◽  
D. J. P. Wijsman ◽  
Y.A. Hekster ◽  
A. Keyser ◽  
W.O. Renier ◽  
...  
Keyword(s):  
The Netherlands ◽  
Epilepsy Treatment

scholarly journals The social context and the need of information from patients with epilepsy: evaluating a tertiary referral service

2015 ◽  
Vol 73 (4) ◽  
pp. 298-303 ◽  
Author(s):  
Priscila Freitas-Lima ◽  
Edna Almeida Monteiro ◽  
Lígia Ribeiro Horta Macedo ◽  
Sandra Souza Funayama ◽  
Flávia Isaura Santi Ferreira ◽  
...  
Keyword(s):  
Refractory Epilepsy ◽  
Developed Countries ◽  
Tertiary Referral ◽  
Educational Levels ◽  
Referral Service ◽  
The Social ◽  
Epilepsy Treatment ◽  
Social Security Benefits ◽  
Patients With Epilepsy ◽  
Structured Questionnaire

Objective Characterize the social profile and the need of information from patients with refractory epilepsy. Method A semi-structured questionnaire was applied to 103 patients to investigate sociodemographic aspects, pharmacotherapy and any doubts about epilepsy. Results Patients were highly dependent on having a free and accessible supply of antiepileptic drugs. Sixty-eight percent of the population was unemployed, and 26% confirmed receiving social security benefits due to epilepsy. Twenty-nine percent of the population reached high school. Eighty-five percent of the patients had at least one doubt about epilepsy; treatment and epilepsy aspects in general were the main topics. Conclusion : As observed in developed countries, patients with refractory epilepsy from a developing country also have high rates of unemployment and low educational levels. The results raise a concern about the need of information about epilepsy by patients and their families, urging the necessity to invest in strategies to solve this deficiency in knowledge.

The potential role of cannabinoids in epilepsy treatment

2017 ◽  
Vol 17 (11) ◽  
pp. 1069-1079 ◽  
Author(s):  
Carmen De Caro ◽  
Antonio Leo ◽  
Rita Citraro ◽  
Caterina De Sarro ◽  
Roberto Russo ◽  
...  
Keyword(s):  
Potential Role ◽  
Epilepsy Treatment
Sign in / Sign up

Export Citation Format

Share Document